Exiqon Q1 Sales Climb 29 Percent on miRNA qPCR, Array Adoption

The Danish company attributed its Q1 performance to "strong growth" in demand for its quantitative PCR products, as well as the launch of new array products during the quarter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories